Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc. exhibits a promising outlook due to the sustained reduction in TRAb levels during the off-treatment period, indicating the potential disease-modifying effects of its FcRn inhibitors in treating Graves' disease (GD). The company demonstrated an impressive responder rate of 81% during the 6-month off-treatment period, which aligns closely with the 70%-80% responder rates observed during active treatment. This consistency reinforces confidence in the durability of the treatment's effectiveness, especially in patients not responsive to antithyroid drug therapy, thus highlighting the robustness of Immunovant's product candidates.

Bears say

Immunovant Inc faces a challenging outlook due to the persistent high levels of TRAbs, which are linked to increased rates of relapse in patients. This implies potential efficacy concerns regarding their primary focus, IMVT-1402, as the interplay between TRAbs and the growth factor pathways has implications for the effectiveness of the treatment. The clinical risk of serious complications, including inflammation and vision threats stemming from TRAbs-mediated interactions, adds further uncertainty to the company's development efforts and market viability.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.